Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811850 · ClinicalTrials.gov registry record · Phase 4
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00811850 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 15 participants.
The verdict
NCT00811850, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
Interventions
- DRUG fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- DRUG fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811850
The ClinicalTrials.gov registry entry for NCT00811850 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution is the first listed.
NCT00811850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811850 about?
NCT00811850 is a clinical study titled "Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow". A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) o...
What is the current status of trial NCT00811850?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00811850?
The interventions under investigation include: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (DRUG), fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00811850?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.